US · NBIX
Neurocrine Biosciences, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- San Diego, CA 92130
- Website
- neurocrine.com
Price · as of 2025-12-31
$131.78
Market cap 13.27B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $174.72 | +32.58% |
| Intrinsic Value(DCF) | $192.45 | +46.04% |
| Graham-Dodd Method(GD) | $56.75 | -56.94% |
| Graham Formula(GF) | $137.57 | +4.39% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $7.99 | $68.97 | $22,067.12 | $4.49 | $90.86 |
| 2012 | $11.24 | $62.55 | $1,396.99 | $2.73 | $0.00 |
| 2013 | $17.50 | $51.44 | $0.97 | $0.00 | $56.83 |
| 2014 | $40.96 | $45.35 | |||
| 2015 | $35.44 | $3.53 | $0.00 | ||
| 2016 | $46.31 | $37.36 | $1.67 | $0.00 | $24.48 |
| 2017 | $92.43 | $168.87 | $6.22 | $0.00 | $0.00 |
| 2018 | $76.86 | $94.81 | $45,045.13 | $6.15 | $39.73 |
| 2019 | $93.06 | $78.47 | $340,616.55 | $8.97 | $32.10 |
| 2020 | $97.06 | $94.89 | $49,684.97 | $33.97 | $172.83 |
| 2021 | $89.29 | $84.64 | $3,981.12 | $19.26 | $15.31 |
| 2022 | $95.81 | $93.84 | $1,033.13 | $25.89 | $61.55 |
| 2023 | $139.22 | $118.12 | $1,326.48 | $35.62 | $86.30 |
| 2024 | $113.04 | $130.73 | $508.48 | $42.73 | $108.28 |
| 2025 | $132.38 | $174.72 | $24.60 | $56.74 | $137.57 |
AI valuation
Our deep-learning model estimates Neurocrine Biosciences, Inc.'s (NBIX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $174.72
- Current price
- $131.78
- AI upside
- +32.58%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$192.45
+46.04% upside
Graham-Dodd
$56.75
-56.94% upside
Graham Formula
$137.57
+4.39% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NBIX | Neurocrine Biosciences, I… | $131.78 | 13.27B | +33% | +46% | -57% | +4% | 27.52 | 4.05 | 4.60 | 18.16 | 65.61 | 4.05 | 98.18% | 21.64% | 16.73% | 16.38% | 20.21% | 11.46% | 0.13 | — | 3.39 | 2.92 | -0.45 | 4195.00% | 2145.00% | 3437.00% | 5.68% | 1.05 | 36.02% | 0.00% | 0.00% | 5.22% | 19.56 | 16.17 | 4.23 | 7.39 |
| COO | The Cooper Companies, Inc… | $83.67 | 16.63B | -16% | -60% | -63% | -71% | 44.52 | 2.03 | 4.08 | 18.38 | — | 5.96 | 60.67% | 16.69% | 9.16% | 4.59% | 4.21% | 3.03% | 0.34 | 6.83 | 1.89 | 0.84 | 2.54 | -459.00% | 506.00% | 5054.00% | 2.60% | 0.72 | 4.04% | 0.00% | 0.00% | 1.74% | 28.35 | 44.65 | 4.73 | 3.88 |
| ELAN | Elanco Animal Health Inco… | $26.40 | 13.12B | +23% | -60% | -95% | — | -55.82 | 1.98 | 2.75 | 24.29 | — | -7.90 | 43.48% | 5.34% | -4.92% | -3.67% | 2.52% | -1.79% | 0.61 | 1.15 | 2.17 | 0.93 | 5.14 | -16912.00% | 622.00% | -2792.00% | 2.19% | 0.35 | 2.84% | 0.00% | 0.00% | 2.94% | 65.17 | 57.83 | 3.48 | 1.49 |
| HOLX | Hologic, Inc. | $75.36 | 16.82B | +9% | -53% | -75% | -67% | 30.11 | 3.37 | 4.15 | 17.05 | — | 20.82 | 61.00% | 17.42% | 13.80% | 11.12% | 10.86% | 6.23% | 0.52 | 16.73 | 3.75 | 2.87 | 0.65 | -2500.00% | 174.00% | -1964.00% | 5.40% | 1.08 | 16.84% | 0.00% | 0.00% | 4.42% | 24.44 | 18.97 | 4.26 | 4.18 |
| ICLR | ICON Public Limited Compa… | $108.14 | 8.26B | +89% | -31% | -50% | -11% | 19.44 | 1.62 | 1.86 | 11.80 | 67.55 | -4.98 | 29.42% | 13.26% | 9.56% | 8.44% | 7.88% | 4.67% | 0.38 | 4.63 | 1.26 | 1.21 | 1.96 | 2878.00% | 199.00% | 963.00% | 7.27% | 0.46 | 8.81% | 0.00% | 0.00% | 6.47% | 16.81 | 16.50 | 2.23 | 2.24 |
| RDY | Dr. Reddy's Laboratories … | $14.38 | 11.97B | -27% | +23% | -53% | +28% | 19.94 | 3.42 | 3.51 | 11.69 | 1373.07 | 5.08 | 58.50% | 22.07% | 17.37% | 18.65% | 19.79% | 13.00% | 0.14 | 25.40 | 1.92 | 1.29 | 0.33 | 145.00% | 1661.00% | -3316.00% | 1.05% | 0.36 | 4.44% | 0.58% | 11.60% | 0.71% | 15.73 | 93.95 | 3.47 | 6.72 |
| SMMT | Summit Therapeutics Inc. | $16.59 | 12.35B | — | — | — | — | -11.21 | 18.37 | — | -14.24 | -3.08 | 18.43 | 0.00% | — | — | -206.10% | 2928.71% | -181.94% | 0.02 | — | 9.87 | 9.77 | 0.26 | 36452.00% | — | 12749.00% | -2.67% | -4.42 | 1166.77% | 0.00% | 0.00% | 0.93% | -14.04 | -35.25 | — | 72.96 |
| SNN | Smith & Nephew plc | $36.90 | 16.13B | +1% | -68% | — | -68% | 30.99 | 2.43 | 2.20 | 12.51 | — | 10.58 | 69.64% | 11.31% | 7.09% | 7.86% | 6.81% | 4.05% | 0.63 | 3.91 | 2.89 | 1.19 | 2.18 | -2167.00% | 470.00% | 23481.00% | 4.75% | 0.64 | 7.59% | 2.56% | 79.40% | 3.19% | 23.55 | 25.53 | 2.66 | 3.29 |
| TEM | Tempus AI, Inc. | $53.25 | 9.2B | +3% | +24,028% | — | — | -37.91 | 18.91 | 7.30 | -42.05 | — | -27.80 | 69.64% | -18.76% | -19.27% | -89.48% | -62.74% | -15.31% | 1.66 | -3.40 | 3.13 | 2.86 | -0.95 | -6937.00% | 8341.00% | 1325.00% | -2.57% | -0.59 | -76.13% | 0.00% | 0.00% | 0.03% | -39.18 | -39.10 | 7.35 | 3.76 |
| UHS | Universal Health Services… | $206.10 | 13.12B | -29% | -58% | -24% | +99% | 8.68 | 1.80 | 0.76 | 6.73 | 23.26 | 3.99 | 11.48% | 11.48% | 8.57% | 21.68% | 12.66% | 10.08% | 0.76 | 12.68 | 1.05 | 0.85 | 1.95 | 3734.00% | 971.00% | -2440.00% | 6.47% | 0.58 | 7.04% | 0.39% | 3.40% | 7.77% | 9.27 | 21.78 | 1.07 | 3.24 |
| VTRS | Viatris Inc. | $14.93 | 17.2B | +55% | -58% | — | — | -5.23 | 1.25 | 1.29 | -79.59 | -1.12 | -2.57 | 35.06% | -18.62% | -24.58% | -21.08% | -8.56% | -8.93% | 0.98 | -5.65 | 5.06 | 2.25 | -33.11 | 46604.00% | -298.00% | -201.00% | 10.54% | 1.20 | 6.49% | 3.05% | -16.00% | 8.39% | -11.82 | 16.25 | 2.20 | 0.88 |
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
- CEO
- Kyle W. Gano
- Employees
- 1.8K
- Beta
- 0.31
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($192.45 ÷ $131.78) − 1 = +46.04% (DCF, example).